EUCTR2015-002693-20-BG进行中（未招募）1 期
A randomized, parallel group, multi-centre phase-2 study of GX-G3 compared with pegfilgrastim as an adjunct to chemotherapy in patients with Non-Hodgkin’s Lymphoma - Parallel group, multi-centre phase-2 study of GX-G3 in patients with Non-Hodgkin's Lymphoma
Ilkogen Ilac San. ve Tic. A.S.0 个研究点目标入组 60 人开始时间: 2015年11月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •[1] Male or female patients =18 years of age (Republic of Korea: =19 years of age)
- •[2] Patients with Non-Hodgkin’s Lymphoma confirmed by immunohistochemistry or flow cytometry:
- •- stage III-IV follicular lymphoma (Ann Arbor staging1) OR
- •- CD20 positive diffuse large B cell non-Hodgkin lymphoma*
- •[3] Patients who fulfil the criteria for receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy for at least 2 cycles of 21 days each
- •[4] Patients who are about to receive the first two cycles of R-CHOP therapy within a series of several cycles (previous exposure to R-CHOP is allowed but in another series of cycles more than 3 months before randomization in the present trial)
- •[5] ECOG performance status 0, 1, or 2
- •[6] Life expectancy with treatment of at least 6 months
- •[7] Patients willing and able (e.g. mental and physical condition) to participate in all aspects of the study, attending scheduled visits, and compliance with protocol requirements as evidenced by providing signed written informed consent
- •*Stage III-IV
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •[1] History of hypersensitivity or intolerance to the active substance or any of the excipients of the study medication (e.g. sorbitol, fructose, or to latex) or to any of the components of R-CHOP therapy
- •[2] Known hypersensitivity to E coli-derived products (e.g., Filgrastim, HUMULIN® Insulin, L-Asparaginase, HUMATROPE® Growth Hormone, INTRON A®)
- •[3] Burkitt's or B-lymphoblastic lymphoma
- •[4] Non-Hodgkin’s Lymphoma with CNS involvement
- •[5] Active infection requiring treatment with systemic (intravenous or oral) antiinfectives (antibiotic, antifungal, antiviral) at baseline
- •[6] Exposure to R-CHOP therapy or pegfilgrastim within the last 3 months before randomization
- •[7] Known lack of neutropenia in patients previously exposed to R-CHOP therapy
- •[8] Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies
- •[9] Any premalignant myeloid condition or any malignancy with myeloid characteristics (e.g., myelodysplastic syndromes, acute or chronic myelogenous leukaemia)
- •[10] Prior malignancy within the last 5 years, with the exception of surgically cured basal cell carcinoma, squamous skin cell carcinoma, or in situ carcinoma of the cervix
- •[11] Prior bone marrow or stem cell transplantation
- •[12] Severe hepatic impairment: serum bilirubin above 51.3 µmol/l (3 mg/dl) or serum albumin below 28 g/l (2.8 g/dl)
- •[13] Baseline neutrophil count <1.5 x 109/l or platelet count <100 x 109/l
- •[14] Demyelinating form of Charcot-Marie-Tooth syndrome
- •[15] Any of the following during the last month before randomization: pneumonia, pulmonary oedema, interstitial lung disease, lung infiltrations
- •[16] Sickle cell trait or sickle cell disease
- •[17] Major surgery within 2 weeks prior to randomization
- •[18] Patient is currently enrolled in, or has completed less than 30 days before the screening examination of the present trial another clinical trial with an investigational drug
- •[19] Previous enrolment in this study
- •[20] Women of childbearing potential unable or unwilling to undergo pregnancy tests and practice adequate contraceptive measures*. Reliable methods for women are hormonal contraceptives**, surgical intervention (e.g. tubal ligation), intrauterine device (IUD) and sexual abstinence
- •[21] Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the study
- •[22] Alcohol/drug dependence or abuse (excluding tobacco abuse)
- •[23] Unreliability or lack of cooperation.
- •[24] Urinary outflow obstruction
- •[25] Impaired cardiac function: myocardial insufficiency, recent (last 6 months) myocardial infarction, severe arrhythmias
- •[26] Any other condition of the patient (e.g., serious or unstable medical or psychological condition, acute psychosis, severe and long-lasting febrile neutropenia) that in the opinion of the investigator may compromise evaluation of the study treatment or may jeopardize patient’s safety, compliance or adherence to protocol requirements
- •[27] Pregnant or bre
研究者
相似试验
进行中（未招募）
不适用
A Phase II multicenter, parallel group, randomized study of palIfosfamide tris plus doxorubiCin versus doxorubicin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO) - PICASSOnresectable or metastatic soft-tissue sarcomaMedDRA version: 9.1Level: LLTClassification code 10039491Term: SarcomaEUCTR2008-004856-57-ITZIOPHARM ONCOLOGY, INC100
进行中（未招募）
不适用
A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bladder (OAB).Overactive bladder (OAB)MedDRA version: 14.0Level: LLTClassification code 10059617Term: Overactive bladderSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-022611-19-EEXention Limited300
进行中（未招募）
1 期
A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bladder (OAB).EUCTR2010-022611-19-BEXention Limited300
进行中（未招募）
不适用
A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bladder (OAB).Overactive bladder (OAB)MedDRA version: 12.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2010-022611-19-GBXention Limited300
进行中（未招募）
1 期
A Study of Aducanumab in Participants With MildCognitive Impairment due to Alzheimer’s Disease orWith Mild Alzheimer’s Disease Dementia to Evaluate theSafety of Continued Dosing in Participants WithAsymptomatic Amyloid-Related Imaging AbnormalitiesMild Cognitive Impairment due to Alzheimer's Disease and Mild Alzheimer's DementiaMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2018-002102-31-ITBIOGEN IDEC RESEARCH LIMITED500